case_images: PMC10601707_01
case_images: a Axial section of abdomen and pelvis CT post-IV contrast showing a large well-defined lobulated heterogeneously enhancing mesenteric mass and PET/CT scan showing increased metabolic activity with photopenic defects which are noted centrally, December 2, 2019. b Progression of disease shown in axial section CT abdomen and pelvis, March 16, 2020.
case_images: cro-2023-0016-0001-532099_F01.jpg
case_images: PMC10601707_01_cro-2023-0016-0001-532099_F01.jpg
case_images: F1
case_images: A diagnosis of SEF with extensive peritoneal carcinomatosis was made as shown in Figure 1a. Figure 1b. Following progression, the decision was for surgical intervention.
case_images: CT abdomen and pelvis showing peritoneal metastasis and progression 5 months after initial HIPEC/CRS, September 2020.
case_images: cro-2023-0016-0001-532099_F02.jpg
case_images: PMC10601707_01_cro-2023-0016-0001-532099_F02.jpg
case_images: F2
case_images: September 2020 as shown in Figure 2, when recurrence warranted a further round of CRS and HIPEC. Subsequently, the patient remained in remission until October 2021, when the disease recurred, as shown in Figure 3.
case_images: CT abdomen and pelvis showing recurrence of disease, October 2021.
case_images: cro-2023-0016-0001-532099_F03.jpg
case_images: PMC10601707_01_cro-2023-0016-0001-532099_F03.jpg
case_images: F3
case_images: September 2020 as shown in Figure 2, when recurrence warranted a further round of CRS and HIPEC. Subsequently, the patient remained in remission until October 2021, when the disease recurred, as shown in Figure 3.
case_images: a CT abdomen and pelvis showing disease progression and pre-crizotinib administration, April 2022. b CT abdomen and pelvis showing a significant mass size regression post-crizotinib dose, May 2022.
case_images: cro-2023-0016-0001-532099_F04.jpg
case_images: PMC10601707_01_cro-2023-0016-0001-532099_F04.jpg
case_images: F4
case_images: CT showed disease progression prior to the administration of crizotinib as shown in Figure 4a. Crizotinib 250 mg was started on May 1, 2022, and a CT abdomen and pelvis performed 2 weeks later showed a significant size regression of the intra-abdominal masses and hepatic metastases with no new metastatic lesions, as shown in Figure 4b.